Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b

In melanoma, the adaptative cell response to BRAF inhibitors includes altered patterns of cytokine production contributing to tumor progression and drug resistance. Among the factors produced by PLX4032-resistant melanoma cell lines, CCL2 was higher compared to the sensitive parental cell lines and...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Vergani, Elisabetta, Di Guardo, Lorenza, Dugo, Matteo, Rigoletto, Sara, Tragni, Gabrina, Ruggeri, Roberta, Perrone, Federica, Tamborini, Elena, Gloghini, Annunziata, Arienti, Flavio, Vergani, Barbara, Deho, Paola, De Cecco, Loris, Vallacchi, Viviana, Frati, Paola, Shahaj, Eriomina, Villa, Antonello, Santinami, Mario, De Braud, Filippo, Rivoltini, Licia, Rodolfo, Monica
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2015
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4826216/
https://ncbi.nlm.nih.gov/pubmed/26684239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6599
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires